ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
![](https://agendia.com/wp-content/uploads/2020/11/subnav-bigimage4-3.png)
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
What Is Chemotherapy?
Along with surgery or radiation therapy, chemotherapy is one of the most common ways to treat cancer. Chemotherapy treatment is designed to destroy cancer cells; it can be used for primary cancer (cancer that Read More
Gene Expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research OF1–OF11, May 2024 Author: Bottosso et al.
Read MoreCost Effectiveness of MammaPrint in Brazil
The Breast 76 (2024) 103752 Author: Mansani et al.
Read MoreImproved Neoadjuvant Chemo Prediction for HR+HER2- ESBC with MP High 2
21st Bossche Mamma Congress 2024, P07 Presenter: O'Shaughnessy et al.
Read MoreNews
Media Releases
MammaPrint High 2 tumors exhibit heightened immune active state
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreMammaPrint & 3-year outcome of CT with/without anthracycline-ASCO 2024
Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline
Read MoreAgendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read MoreGerman Gynecological Oncology Group (AGO) includes BluePrint® in Guidelines
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
Read More